stockrow
Monday 9 November 2026
Export BJDX’s income statement to Excel — free account
Bluejay Diagnostics, Inc.
BJDXBluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00.
- EPS
- +80.1%
- Free cash flow
- +20.1%
Quarter to June 2026, against a year earlier
2.35
0.16
+7.31%
Follow BJDX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 19.64 | — | — | — | 0.00 | +19.6 pt | ||||||
| EBT | — | — | — | (1) | (1) | (3) | (9) | (10) | (8) | (7) | (7) | +42.4% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | (3,733.69) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (1) | (1) | (3) | (9) | (10) | (8) | (7) | (7) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 415.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (8,336.49) | (11,777.92) | (13,120.00) | (14,720.00) | (14,525.92) | (456.76) | (15.25) | (8.67) | (65.0%) | ||||||
| Cash flow | — | — | — | (16,901.00) | (5,087.00) | (16,396.20) | (12,902.67) | (12,132.65) | (170.76) | (13.48) | (2.84) | (69.5%) | ||||||
| Capex | — | — | — | (60.00) | 0.00 | (89.74) | (1,998.83) | (1,027.65) | (6.70) | (0.39) | (0.16) | (56.9%) | ||||||
| Free cash flow | — | — | — | (16,961.00) | (5,087.00) | (16,485.94) | (14,901.50) | (13,160.31) | (177.46) | (13.87) | (3.00) | (69.4%) | ||||||
| Book value | — | — | — | (29,324.00) | (42,062.00) | 76,527.99 | 19,235.50 | 4,224.44 | 125.10 | 13.31 | 4.53 | n/m | ||||||
| Shares, m | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | +306.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | 0.65 | — | — | — | 0.52 | — | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | (0.24) | — | — | — | (0.01) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (2) | (1) | (4) | (8) | (8) | (8) | (6) | (6) | +23.7% | |||||
| Capex | — | — | — | 0 | — | 0 | (1) | (1) | 0 | 0 | 0 | +75.2% | ||||||
| Free cash flow | — | — | — | (2) | (1) | (4) | (9) | (9) | (8) | (6) | (6) | +24.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | (1) | 20 | 10 | 1 | 4 | 4 | 8 | n/m | |||||
| Net debt | — | — | — | 1 | (1) | (19) | (10) | (2) | (4) | (5) | (10) | n/m | ||||||
| Shareholders’ equity | — | — | — | (3) | (4) | 20 | 12 | 3 | 6 | 6 | 9 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (178.90) | (95.18) | (30.96) | (53.83) | (108.25) | (363.37) | (99.42) | (81.07) | +79.5 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (151.35) | (408.30) | (939.02) | (313.88) | (536.23) | 0.00 | (536.2) pt | ||||||
| ROE | — | — | — | 22.97 | 32.45 | (43.13) | (58.25) | (137.90) | (485.63) | (117.02) | (98.89) | (140.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 6 | 9 | 16 | 10 | 7 | 6 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · latest quarter Jun 2022 · fundamentals updated 26 Oct 2026
Bluejay Diagnostics, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VVOS Vivos Therapeutics, Inc. | $3.2M | — (loss-making) | — (loss-making) | +34.90% (above 0%: growing) | n/m | +16.44% (above 0%: growing) | 57.31% | (93.63%) | Compare |
| AMIX Autonomix Medical, Inc. | $3.0M | — (loss-making) | — | — | n/m | −36.10% (below 0%: shrinking) | — | 0.00% | Compare |
| BJDX Bluejay Diagnostics, Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | |
| AIDX 20/20 Biolabs Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | −23.98% (below 0%: shrinking) | 41.71% | (170.30%) | Compare |
| IVF INVO Fertility, Inc | $2.6M | — (loss-making) | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| NUWE Nuwellis, Inc. | $2.5M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| CODX Co-Diagnostics, Inc. | $2.4M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| ICCM IceCure Medical Ltd. | $2.3M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $2.5M | — | — | +14.14% | — | +1.42% | 41.71% | (127.28%) |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
6.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement